NBP — NovaBridge Biosciences
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1778016 ·
Last close
$1.86
Market Cap
$215.11M
52W High
$3.86
52W Low
$1.67
ADV30
1,083,104
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -72,900,000 | -30,787,000 | 260,522,000 | 210,632,000 | 29,581,000 |
| Sep 2025 | 0 | — | -8,989,000 | -6,828,000 | 277,410,000 | 228,064,000 | 18,495,000 |
| Jun 2025 | 0 | — | -7,114,000 | -5,504,000 | 206,708,000 | 165,404,000 | 9,975,000 |
| Mar 2025 | 0 | — | -5,266,000 | -3,150,000 | 208,941,000 | 53,597,000 | 10,600,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,284,000
Investing CF
$-81,764,000
Financing CF
$57,725,000
CapEx
$-39,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.37
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,332,308,000
Inventory
—
Receivables
$1,793,000
ST Investments
$210,000
EBIT TTM
$-94,269,000
Pretax Income TTM
$-88,340,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -94,269,000 | -46,269,000 | 260,522,000 | 29,581,000 | — | -20,597,000 |
| Dec 2024 | 0 | -51,426,000 | -22,230,000 | 212,680,000 | 11,520,000 | — | -52,669,000 |
| Dec 2023 | 632,000 | -48,976,000 | -207,729,000 | 368,922,000 | 126,338,000 | — | -72,697,000 |
| Dec 2022 | -1,551,000 | -53,078,000 | -371,053,000 | 590,446,132 | 168,678,417 | — | -49,582,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CAMP | Camp4 Therapeutics Corp | $212.90M | $4.10 | — |
| NKTX | Nkarta, Inc. | $218.93M | $3.06 | — |
| HELP | CYBIN INC. | $221.03M | $4.43 | — |
| KROS | Keros Therapeutics, Inc. | $222.26M | $11.23 | — |
| RNA | Atrium Therapeutics, Inc. | $223.40M | $13.06 | — |
News headlines (Yahoo Finance, 1h cache)
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
2026-05-12 11:00 · Yahoo
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
2026-04-22 11:00 · Yahoo
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
2026-04-07 20:50 · Yahoo
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
2026-03-16 11:00 · Yahoo
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
2026-03-09 11:00 · Yahoo
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
2026-03-03 14:05 · Yahoo
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
2026-03-02 12:00 · Yahoo
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
2026-02-19 12:00 · Yahoo
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
2026-02-17 21:05 · Yahoo
Amazon downgraded, Roblox upgraded: Wall Street's top analyst calls
2026-02-06 14:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.